Clover Health Stock Erupts 14% on Smaller-than-expected Loss, Analyst Sees ‘Clean Quarter’ By

© Reuters. Clover Health (CLOV) Stock Erupts 14% on Smaller-than-expected Loss, Analyst Sees ‘Clean Quarter’

Shares of Clover Health (NASDAQ:) are up greater than 14% in premarket buying and selling Tuesday after the corporate reported better-than-expected Q1 income.

CLOV reported of $874.4 million, whereas analysts have been searching for $790.3 million. Net loss totaled $75.3 million within the interval. CLOV reported an adjusted EBITDA lack of $71.8 million, in comparison with the anticipated lack of $112.1 million.

For the complete fiscal 12 months, Clover Health expects income within the vary of $3 billion to three.4 billion, in comparison with the consensus estimates of $3.24 billion.

“2022 is off to a strong start, led by significant year-over-year revenue growth and quarter-over-quarter margin improvements in insurance (medicare advantage) and non-insurance (direct contracting),” mentioned Clover Health CEO Vivek Garipalli.

Bank of America analyst Kevin Fischbeck reiterated an Underperform score on CLOV inventory however mentioned outcomes demonstrated “a first step to restoring confidence.”

“The focus is shifting to going deeper in existing markets, where growth is likely slower but the path to profitability is clearer. Overall, Q1 showed progress and is a good first step towards restoring confidence in the trajectory, but similar to CLOV’s own outlook we remain cautious until the outperformance is sustained throughout the year,” Fischbeck mentioned in a consumer word.

Cowen analyst Gary Taylor reiterated a Market Perform score and a $3.00 per share value goal. The analyst nonetheless expects CLOV to boost fairness capital this 12 months.

“We are skeptical regarding CLOV’s core business thesis; that overlaying Clover Assistant (CA) on top of unmanaged FFS physician practices will yield best-in-class care management and per-capita medical costs. The company’s MA business risks all on this thesis. Further, CLOV is quadrupling its total actuarial risk profile by 2022 via participation in CMS’ new and untested Direct Contracting (DC) program,” Taylor wrote in a memo.

By Senad Karaahmetovic

Source hyperlink

Leave a Reply

Your email address will not be published.